The global hormone replacement therapy (HRT) market is projected to reach USD 35.60 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030, according to a new study by Grand View Research Inc. This market expansion is primarily driven by the rising prevalence of hormonal disorders and advancements in drug delivery systems. For instance, approximately 70,000 individuals in the U.S. suffer from hypoparathyroidism, a condition involving hormone imbalances, according to the National Organization of Rare Diseases.

A significant factor contributing to the market growth is the ongoing technological improvements aimed at reducing side effects and increasing the bioavailability of hormone therapy drugs. Higher bioavailability allows for more effective treatments, which can, in turn, reduce the frequency of administration. For example, products like NGENLA, designed to treat growth hormone deficiencies, only require a once-a-week dosage, thereby improving patient compliance with treatment regimens. Moreover, improvements in drug administration routes are anticipated to further enhance market adoption. Intranasal estrogen medications, such as Nafarelin, offer greater patient compliance compared to traditional oral or injection methods, especially among women, due to their convenience and ease of use.

Pharmaceutical companies are adopting strategies such as partnerships and collaborations to expand their market presence and drive revenue growth. A notable example is Merck & Co., Inc.’s agreement with BIOCORP in September 2021 to develop and distribute the HGH monitoring device, Mallya. This device helps in tracking daily human chorionic gonadotropin (HCG) treatment, which is essential for various hormone-related conditions. Such initiatives are expected to support market growth throughout the forecast period.

Additionally, the introduction of new hormone replacement therapy medications is set to further fuel the market. For instance, in November 2021, Fuji Pharma Co., Ltd. launched F-meno (100 mg capsule) to prevent endometrial hyperplasia in patients undergoing estrogen therapy for menopausal disorders. This oral medication was added to Japan’s National Health Insurance Drug Price list, which could significantly increase its prescription rates and, in turn, contribute to market growth.

Get a preview of the latest developments in the Hormone Replacement Therapy Market? Download your FREE sample PDF copy today and explore key data and trends. 

FAQ for the Global Hormone Replacement Therapy Market

1. What is the global hormone replacement therapy (HRT) market size?

The global hormone replacement therapy market is expected to reach USD 35.60 billion by 2030, growing at a compound annual growth rate (CAGR) of 6.6% from 2023 to 2030.

2. What are the key drivers of growth in the hormone replacement therapy market?

The market growth is driven by the increasing prevalence of hormonal disorders, advancements in drug delivery systems, and the rising demand for better patient compliance. Additionally, innovations in bioavailability and the introduction of new drugs are also significant factors.

3. How are technological advancements impacting the hormone replacement therapy market?

Technological advancements have improved drug bioavailability, reduced side effects, and enhanced patient compliance. For example, products like NGENLA require a once-a-week dosage, which increases patient adherence to treatment plans. Improved administration routes, such as intranasal estrogen medications, also contribute to better patient compliance.

4. What are some recent collaborations in the hormone replacement therapy market?

In September 2021, Merck & Co., Inc. partnered with BIOCORP for the development and distribution of the HGH monitoring device, Mallya. This device is used to monitor and track daily HCG treatment, enhancing market growth.

5. How are new drug launches affecting the hormone replacement therapy market?

The launch of new drugs is expected to drive market growth. For example, Fuji Pharma Co., Ltd. launched F-meno (100 mg capsule) in November 2021, which is used to prevent endometrial hyperplasia in patients undergoing estrogen therapy for menopausal disorders. This new medication has been added to Japan's National Health Insurance Drug Price list, likely boosting its prescription rate.

6. What are the challenges facing the hormone replacement therapy market?

The market faces challenges due to severe adverse effects linked to certain estrogen therapy drugs, such as Premarin and Prempro, which have been associated with increased cancer risks. These safety concerns can limit the market growth, especially in regions with stringent regulatory frameworks.

Order a free sample PDF of the Hormone Replacement Therapy Market Intelligence Study, published by Grand View Research.